Key result
In a real-world cohort of patients with cardiogenic shock, Impella support was associated with an overall in-hospital mortality of 42% and a 52% rate of significant hemolysis.
Why the study?
Data are scarce on the specific clinical setting and potential role of Impella devices in patients with cardiogenic shock from routine clinical practice.
Does Impella support improve in-hospital mortality in patients with cardiogenic shock?
Cohort (n=50)
No
Does Impella support improve in-hospital mortality in patients with cardiogenic shock?
In real-world practice, Impella support in cardiogenic shock shows acceptable mortality, particularly as a bridge to transplantation in profound shock, despite a significant rate of complications.
Cautions against Impella in older or profound CS; leaves open BTT use in cardiomyopathy.
BACKGROUND: The Impella pump has emerged as a promising tool in patients with cardiogenic shock (CS). Despite its attractive properties, there are scarce data on the specific clinical setting and the potential role of Impella devices in CS patients from routine clinical practice. METHODS: from April 2015 to December 2020 were included. Baseline characteristics, management and outcomes were assessed according to CS severity, age and cause of CS. Main outcome measured was in-hospital mortality. RESULTS: = 11) presented with profound CS. In 90.9% of these cases, Impella support was used as a bridge to cardiac transplantation. There were no cases of death. CONCLUSIONS: In this cohort of real-life CS patients, Impella devices were used in different settings, with different clinical profiles and management. Despite a significant rate of complications, mortality was acceptable and lower than those observed in other series.
No takes yet. Share an insight, caveat, or question.
Barrionuevo-Sánchez et al. (2022) conducted a cohort in Cardiogenic shock (n=50). Impella support was evaluated on In-hospital mortality. In a real-world cohort of patients with cardiogenic shock, Impella support was associated with an overall in-hospital mortality of 42% and a 52% rate of significant hemolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: